Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066141 | 0.94 | SLC9A1 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL49175 | 0.94 | SLC9A1 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phosphoric Acid SCHEMBL19406124 | 0.90 | SLC9A1 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phosphoric Acid SCHEMBL29515149 | 0.89 | NPSR1 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Lindane SCHEMBL20797313 | 0.88 | TSHR (0.36) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29399678 | 0.85 | SLC9A1 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7270165 | 0.84 | SLC9A1 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Fluoride Ion SCHEMBL6345 | 0.84 | SLC9A1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phosphine SCHEMBL30298295 | 0.84 | SLC9A1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL30591144 | 0.84 | SLC9A1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | UNIV INDIANA TRUSTEES (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4313163-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Ambrx, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023122753-A1 | CROSSLINKING ANTIBODIES | ENLAZA THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022212899-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220204961-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | UNIV INDIANA TRUSTEES (US) | 2022-06-30 | — | — | US | disclosed |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3923991-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | Ambrx, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3849592-A1 | MODIFIED IFNL3 POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY AND THEIR USES | Exalt Therapeutics, LLC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20110098217-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110065633-A1 | ESTER-BASED PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-03-17 | — | — | US | disclosed |
| US-20100331246-A1 | ESTER-BASED INSULIN PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2249853-A1 | ESTER-BASED PEPTIDE PRODRUGS | Indiana University Research and Technology Corporation (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2217701-A2 | GLUCAGON ANTAGONISTS | Indiana University Research and Technology Corporation (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2214691-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | Indiana University Research and Technology Corporation (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009099763-A1 | ESTER-BASED PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009058734-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058662-A2 | GLUCAGON ANTAGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065633-A1 | ESTER-BASED PEPTIDE PRODRUGS | VIP, DNPEP, PEPD | HDAC3 1709/4885HDAC4 1326/4885HDAC1 1819/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | HDAC3 495/4885HDAC4 727/4885HDAC1 841/4885 |
| US-20100331246-A1 | ESTER-BASED INSULIN PRODRUGS | IAPP, IDE, GCG | HDAC3 990/4885HDAC4 815/4885HDAC1 1216/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | HDAC3 1035/4885HDAC4 1324/4885HDAC1 2165/4885 |
| US-20240084283-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | DDAH1, ADM2, NPPA | HDAC3 4279/4885HDAC4 4427/4885HDAC1 4470/4885 |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | TLR1, TLR3, TLR2 | HDAC3 1184/4885HDAC4 1304/4885HDAC1 2503/4885 |
| US-20110098217-A1 | COMPOUNDS EXHIBITING GLUCAGON ANTAGONIST AND GLP-1 AGONIST ACTIVITY | GLP1R, GIPR, GCGR | HDAC3 3331/4885HDAC4 3612/4885HDAC1 3479/4885 |
| US-20220204961-A1 | MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCING MOIETY, IMPROVED PHARMACOLOGY AND THEIR USES | DDAH1, ADM2, NPPA | HDAC3 4279/4885HDAC4 4427/4885HDAC1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.